Identification of new types of biomarkers and tracers for the in vivo molecular imaging of the pancreatic Beta-cell mass (KeyMarker)


At a Glance
  • Status: Completed Consortium
  • Year Launched: 2011
  • Initiating Organization: IBA Group
  • Initiator Type: Industry
  • Disease focus:
    Type 2 Diabetes
  • Location: Europe

Abstract

Mission

The goal of KeyMarker is to identify molecules that can be used as radiotracers for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging and potential quantification of the pancreatic beta-cell mass. Such molecules may lead to novel approaches for diabetic disease management, such as patient stratification, disease follow-up, and therapeutic options. Several ligands for the target will be screened and evaluated through the preclinical models developed for the project. The in vitro/in vivo preclinical platform as well as the toxicology, bio-distribution, and labeling expertise dedicated to the project form the basis for a standard process for further diabetes imaging tracer evaluation.

Financing

This was a three-year project with a total budget of €2.7 million.

Points of Contact

Richard Zimmermann (project coordinator)
email: richard.zimmermann@iba-group.com

Sponsors & Partners

Eurogenetic

FUNDP

IBA

Trasis

UCL

ULB

ULg


Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.